A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

Thalassemia Clinical Trial

Official title:

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03692052
• Other study ID #: AG348-C-010
• Secondary ID: 2018-002217-35
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 20, 2019
• Est. completion date: September 30, 2030

Study information

• Verified date: June 2024
• Source: Agios Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study AG348-C-010 is a multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of treatment with AG-348 in adult participants with non-transfusion-dependent thalassemia (NTDT). This study includes a core period (up to 24 weeks) followed by an extension period (up to 10 years) for eligible participants. 20 participants with NTDT were enrolled. The initial dose of AG-348 was 50 milligrams (mg) twice daily (BID) with one potential dose-level increase to 100 mg BID at the Week 6 visit based on the participant's safety and hemoglobin (Hb) concentrations.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: September 30, 2030
• Est. primary completion date: August 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Informed consent;

• Known medical history of thalassemia, including ß-thalassemia intermedia, Hb E ß-thalassemia, a-thalassemia (Hb H disease), or ß-thalassemia with mutations of 1 or more a genes;

• Documented clinical laboratory confirmation of thalassemia by Hb electrophoresis/high-performance liquid chromatography (HPLC) or deoxyribonucleic acid (DNA) analysis, either from medical records or during the screening period;

• Hb concentration =10.0 grams per deciliter (g/dL), regardless of sex, based on an average of at least 2 Hb measurements (separated by a minimum of 7 days) during the screening period;

• Considered non-transfusion-dependent, defined as having no more than 5 units of red blood cells (RBCs) transfused during the 24-week period up to the first day of study drug and no RBC transfusions in the 8 weeks prior to the first day of study drug;

• Adequate organ function;

• For women of reproductive potential: negative serum pregnancy test during the screening period and a negative serum or urine pregnancy test on Day 1;

• For women of reproductive potential as well as men with partners who are women of reproductive potential: be abstinent as part of their usual lifestyle, or agreement to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of study drug for women and 90 days following the last dose of study drug for men;

• Willingness to comply with all study procedures for the duration of the study;

Exclusion Criteria:

• Known history of diagnosis of Hb S or Hb C forms of thalassemia;

• Significant medical condition that confers an unacceptable risk to participating in the study, and/or could confound the interpretation of the study data;

• Splenectomy scheduled during the study treatment period or having undergone splenectomy within 12 months prior to signing informed consent;

• Currently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo;

• Exposure to any investigational drug, device, or procedure within 3 months prior to the first day of study drug;

• Prior exposure to sotatercept (ACE-011), luspatercept (ACE-536), ruxolitinib, or gene therapy;

• Prior bone marrow or stem cell transplant;

• Currently pregnant or breastfeeding;

• History of major surgery within 6 months of signing informed consent;

• Currently receiving medications that are strong inhibitors of cytochrome P450 (CYP)3A4, strong inducers of CYP3A4, strong inhibitors of P-glycoprotein (P-gp), or digoxin (a P-gp sensitive substrate medication) that have not been stopped for a duration of at least 5 days or a timeframe equivalent to 5 half-lives (whichever is longer) prior to the first day of study drug;

• Currently receiving chronic anticoagulant therapy, unless started and on a stable dose for at least 28 days prior to first day of study drug;

• Currently receiving anabolic steroids, including testosterone preparations, if initiated =28 days prior to the first day of study drug;

• Currently receiving hematopoietic stimulating agents (e.g., erythropoietins, granulocyte colony stimulating factors, thrombopoietins), if initiated =8 weeks prior to the first day of study drug;

• History of allergy to sulfonamides if characterized by acute hemolytic anemia, drug-induced liver injury, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson syndrome, cholestatic hepatitis, or other serious clinical manifestations;

• History of allergy to AG-348 or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, and mannitol).

Related Conditions & MeSH terms

• Thalassemia

Intervention

Drug:
• AG-348
AG-348 tablet orally BID

Locations

Country	Name	City	State
Canada	University Health Network (Toronto General Hospital)	Toronto	Ontario
United Kingdom	Imperial College Healthcare NHS Trust (Hammersmith Hospital)	London
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	UCSF Benioff Children's Hospital Oakland	Oakland	California

Sponsors (1)

Lead Sponsor	Collaborator
Agios Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Canada,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Achieving a Hemoglobin Response (HR)	HR was defined as a =1.0 gram per deciliter (g/dL) increase in Hb concentration from Baseline at 1 or more assessments between Week 4 and Week 12 (inclusive). A participant's Baseline Hb concentration was defined as the average of all the participant's available Hb concentrations during the screening period up to the first dose of study drug.	Up to 12 weeks
Secondary	Average Change From Baseline in Hb Concentrations From Week 12 to Week 24	A participant's Baseline Hb concentration was defined as the average of all the participant's available Hb concentrations during the screening period up to the first dose of study drug.	Baseline, Week 12 to Week 24
Secondary	Percentage of Participants Achieving a Sustained Hb Response (sHR)	sHR was defined as achieving HR and achieving a =1.0 g/deciliter (dL) increase in Hb concentration at 2 or more evaluable Hb assessments out of the 4 scheduled assessments between the Week 12 visit and Week 24 visit.	Week 12 to Week 24
Secondary	Percentage of Participants Achieving a Delayed Hb Response	Delayed Hb response was defined as not achieving HR and achieving a =1.0 g/dL increase in Hb concentration at 1 or more Hb assessments after Week 12.	Week 12 to Week 24
Secondary	Change From Baseline in Hb Concentration Over the Duration of the Extension Period		Baseline up to approximately 10.5 years
Secondary	Time to First =1.0 g/dL Increase in Hb Concentration		Up to Week 24
Secondary	Change From Baseline in Reticulocyte Count		Up to approximately 10.5 years
Secondary	Change From Baseline in Bilirubin		Up to approximately 10.5 years
Secondary	Change From Baseline in Lactate Dehydrogenase (LDH)		Up to approximately 10.5 years
Secondary	Change From Baseline in Haptoglobin		Up to approximately 10.5 years
Secondary	Change From Baseline in Nucleated Red Blood Cells (NRBCs)		Up to approximately 10.5 years
Secondary	Change From Baseline in Erythropoietin (EPO)		Up to approximately 10.5 years
Secondary	Change From Baseline in Soluble Transferrin Receptor		Up to approximately 10.5 years
Secondary	Drug Concentrations Over Time for AG-348		Predose (60 minutes) and 0.00 hour, 0.50 hour, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Secondary	AUC0-8h: Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours of AG-348		Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Secondary	AUC0-t: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration of AG-348		Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Secondary	Cmax: Maximum Observed Plasma Concentration of AG-348		Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Secondary	Tmax: Time to Reach the Maximum Plasma Radioactivity Concentration (Cmax)		Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Secondary	Tlast: Time of the Last Quantifiable Concentration of AG-348		Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Secondary	Ctrough: Observed Plasma Concentration at the End of a Dosing Interval of AG-348		Predose (60 minutes) and 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours postdose on Day 1 and Week 12
Secondary	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), and TEAEs Leading to Study Drug Dose Reduction, Study Drug Interruption, and Study Drug Discontinuation	An AE is any unfavorable and unintended sign, symptom, or disease, whether or not related to the investigational product. A TEAE was defined as any AE with onset post study drug treatment. An SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically important. AESIs are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESIs included protocol-specified transaminase increase.	From signing the inform consent form up to data cut-off date: 20 August 2020 (Up to approximately 19 months)